CyTuVax   Report issue

For profit Phase 2
Founded: Maastricht Netherlands (2012)

Organization Overview

First Clinical Trial
2015
NCT02540538
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

CyTuVax